United Community Banks, Inc. Announces Completion of Strategic Initiatives That Simplify and Strengthen Balance Sheet; Increased Share Repurchase Authorization

UCB presented data at the EADV 2026 Congress showing earlier treatment with Bimzelx leads to higher resolution rates in hidradenitis suppurativa. At three years, 47.4% of early-treated patients achieved IHS4-100, compared to 33.3% of late-treated patients. Biotherapy-naive patients saw up to 78.8% complete resolution of draining tunnels. The company is expanding its presence beyond this condition.

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.

Nine mid-sized drug manufacturers, including Teva Pharmaceuticals and Sun Pharma, agreed to lower U.S. drug prices under 'most-favored-nation' deals, joining 17 others. The deals cover 89% of the U.S. branded drug market, aiming to save billions for Medicaid and ensure U.S. access to lower prices. Companies committed $19.6B to U.S. manufacturing and donated key pharmaceutical ingredients to a national reserve.

Nine mid-sized pharma companies, including Teva, signed MFN pricing deals with the White House, covering 89% of the US branded drug market. The policy ties US drug prices to the lowest prices charged abroad. The administration claims the deals will reduce prices for costly, chronic, and rare diseases and secure $20B in US manufacturing investments. Public Citizen criticizes the deals as ineffective.

The Trump administration signed MFN drug pricing agreements with nine mid-sized pharma companies, expanding price reduction policies. The firms include Alcon, Astellas Pharma, and Teva, among others. The deals aim to lower U.S. drug prices for treatments like cancer and Parkinson's, with companies investing $19.6B in U.S. manufacturing. The agreements also address API supply chain stability, with companies donating key ingredients to the U.S. reserve.